

TABLE 84: PATIENT CHARACTERISTICS — STUDIES OF TREATMENT-NAIVE PATIENTS FROM TR0007

AUTHOR, YEAR, STUDY NAME	TREATMENT GROUP	ITT, N	AGE, MEAN (SD) OR MEDIAN (RANGE)	% MALE	HCV GENOTYPE SUBTYPE (%)		METAVIR FIBROSIS SCORE (%)					VIRAL LOAD, MEAN LOG ₁₀ (SD)
					1a	1b	F0	F1	F2	F3	F4	
Studies not included in the NMA												
Buti et al. 2014, OPTIMIZE	T12 PR24/48 2a RGT q8	371	48 (11)	63	56	43	48 ^a		23	16	13	6.5 (0.7)
	T12 PR24/48 2a RGT q12	369	48 (11)	57	57	43	47 ^a		26	13	15	6.5 (0.7)
Fried et al. 2013, PILLAR (C205)	PR48 2a	77	45 (21 to 67)	51	38	NR	12	46	34	9	0	6.4 (0.6)
	SIM12 PR24/48 2a RGT	77	47 (18 to 69)	56	49	NR	16	42	34	9	0	6.5 (0.5)
Jacobson et al. 2011, ADVANCE	PR48 2a	361	49 (18 to 69)	58	58	42	41 ^a		39	14	6	6.3 (0.7)
	T12 PR24/48 2a RGT q8	363	49 (19 to 69)	59	59	41	37 ^a		43	14	6	6.3 (0.7)
Marcellin et al. 2011, C208	T12 PR24/48 2a RGT q8	40	46.5 (23 to 63)	50	53	45	38 ^a		40	20	3	6.4 (NR)
	T12 PR24/48 2b RGT q8	42	45.5 (20 to 65)	48	55	45	36 ^a		38	24	2	6.7 (NR)

AUTHOR, YEAR, STUDY NAME	TREATMENT GROUP	ITT, N	AGE, MEAN (SD) OR MEDIAN (RANGE)	% MALE	HCV GENOTYPE SUBTYPE (%)		METAVIR FIBROSIS SCORE (%)					VIRAL LOAD, MEAN LOG ₁₀ (SD)
					1a	1b	F0	F1	F2	F3	F4	
	T12 PR24/48 2a RGT q12	40	40 (22 to 61)	53	53	48	55 ^a		28	18	0	6.5 (NR)
	T12 PR24/48 2b RGT q12	39	49 (19 to 63)	49	44	56	28 ^a		33	31	5	6.7 (NR)
Poordad et al. 2011, SPRINT-2	PR48 2b	363	49 (10)	57	63	33	5	68	18	3	4	6.5 (NR)
	B24 PR28/48 2b RGT	368	50 (9)	62	64	34	5	65	17	5	4	6.5 (NR)
Studies not included in the NMA												
Sherman et al. 2011, ILLUMINATE	T12 PR24 2a RGT eRVR q8	162	51 (22 to 70)	64	71	28	28 ^a		48	12	11	6.3 (0.9)
	T12 PR48 2a RGT eRVR q8 ^b	160	50 (19 to 67)	61	73	27	30 ^a		49	13	8	6.4 (0.7)
	T12 PR48 2a RGT no eRVR q8	118	51 (20 to 63)	59	71	28	23 ^a		42	25	10	6.7 (0.6)
	Discontinued before week 20 ^b	100	52 (21 to 66)	54	72	27	26 ^a		38	17	19	6.4 (0.7)

B = boceprevir; eRVR = extended rapid virological response; F0 = no fibrosis; F1 = portal fibrosis without septa; F2 = portal fibrosis with rare septa; F3 = numerous septa without cirrhosis; F4 = cirrhosis; HCV = hepatitis C virus; ITT = intention-to-treat; NMA = network meta-analysis; NR = not reported; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; RGT = response-guided therapy; SD = standard deviation; T = telaprevir.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.

^a Proportion of patients with METAVIR F0 or F1.

^b Not a Health Canada–recommended dosage regimen.